Recital 2, Regulation (EU) 2021/1686

In forcesince 7 Jul 2021

Article 47 of Commission Delegated Regulation (EU) 2016/161 [Commission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83/EC of the European Parliament and of the Council by laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use (OJ L 32, 9.2.2016, p. 1).] provides that where, following a notification as referred to in Article 46 of that Regulation, the Commission or a Member State considers, on the basis of casualties or hospitalisations of citizens of the Union due to exposure to falsified medicinal products, rapid action is required to protect public health, the Commission is to assess the notification without delay and at the latest within 45 days. In order to better fulfil the objective of that Article, the reference to citizens of the Union should be replaced by a reference to people in the Union as all adverse events in the Union should be considered and monitored regardless of citizenship.